JPMorgan Chase & Co’s Prelude Therapeutics PRLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.58K | Sell |
1,949
-21,831
| -92% | -$17.7K | ﹤0.01% | 5683 |
|
|
2025
Q1 | $18.3K | Sell |
23,780
-37,369
| -61% | -$28.7K | ﹤0.01% | 5309 |
|
|
2024
Q4 | $78K | Buy |
61,149
+55,183
| +925% | +$70.4K | ﹤0.01% | 4860 |
|
|
2024
Q3 | $12.4K | Buy |
5,966
+106
| +2% | +$219 | ﹤0.01% | 5286 |
|
|
2024
Q2 | $22.3K | Sell |
5,860
-387
| -6% | -$1.47K | ﹤0.01% | 5121 |
|
|
2024
Q1 | $29.6K | Sell |
6,247
-3,133
| -33% | -$14.9K | ﹤0.01% | 5136 |
|
|
2023
Q4 | $40.1K | Sell |
9,380
-7,973
| -46% | -$34K | ﹤0.01% | 5069 |
|
|
2023
Q3 | $53.6K | Buy |
17,353
+8,014
| +86% | +$24.8K | ﹤0.01% | 4887 |
|
|
2023
Q2 | $42K | Buy |
9,339
+7,945
| +570% | +$35.8K | ﹤0.01% | 4898 |
|
|
2023
Q1 | $8K | Buy |
1,394
+97
| +7% | +$557 | ﹤0.01% | 5319 |
|
|
2022
Q4 | $8K | Sell |
1,297
-1,154
| -47% | -$7.12K | ﹤0.01% | 5148 |
|
|
2022
Q3 | $16K | Buy |
2,451
+418
| +21% | +$2.73K | ﹤0.01% | 4979 |
|
|
2022
Q2 | $11K | Sell |
2,033
-7,231
| -78% | -$39.1K | ﹤0.01% | 5163 |
|
|
2022
Q1 | $64K | Buy |
9,264
+2,040
| +28% | +$14.1K | ﹤0.01% | 4923 |
|
|
2021
Q4 | $91K | Buy |
7,224
+205
| +3% | +$2.58K | ﹤0.01% | 4868 |
|
|
2021
Q3 | $220K | Buy |
7,019
+130
| +2% | +$4.08K | ﹤0.01% | 4362 |
|
|
2021
Q2 | $197K | Buy |
6,889
+594
| +9% | +$17K | ﹤0.01% | 4507 |
|
|
2021
Q1 | $273K | Sell |
6,295
-18,201
| -74% | -$789K | ﹤0.01% | 4338 |
|
|
2020
Q4 | $1.75M | Buy |
+24,496
| New | +$1.75M | ﹤0.01% | 3046 |
|